Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals plc reports developments across a global biopharma portfolio focused on rare diseases, including epilepsies, cancers and sleep disorders. Recurring updates cover commercial performance for Xywav, Epidiolex and oncology products, plus medical-conference data and real-world evidence for neuroscience and oncology programs.
Company news also includes regulatory and clinical progress for Ziihera (zanidatamab-hrii) in HER2-expressing tumors, including gastroesophageal adenocarcinoma and biliary tract cancer, along with research involving Zepzelca, Modeyso and other pipeline candidates. Updates frequently address financial results, guidance, investor conferences, collaborations and portfolio strategy.
Jazz Pharmaceuticals has announced the top-line results from their Phase 2b clinical trial for suvecaltamide (JZP385), targeting essential tremor (ET). The study did not achieve statistical significance at 30mg versus placebo on primary and key secondary endpoints. Noteworthy, numeric improvements were observed, although they were not statistically significant. The placebo group showed higher-than-expected improvements, surpassing those in the previous T-CALM trial. The drug was well tolerated with a consistent safety profile and no new safety signals. Common adverse events included dizziness, headache, paresthesia, diarrhea, and insomnia, mostly mild to moderate. Jazz is analyzing the data to understand the results better and is awaiting results from a trial on Parkinson's disease tremor expected in Q1 2025.
Jazz Pharmaceuticals presented long-term follow-up results from the HERIZON-BTC-01 Phase 2b trial at ASCO 2024, showcasing the efficacy of zanidatamab in treating HER2-positive biliary tract cancer (BTC). The study reported a median overall survival (OS) of 15.5 months for all patients, with 18.1 months for those with IHC 3+ tumors and 5.2 months for IHC 2+ tumors. The median duration of response (DoR) increased to 14.9 months. The confirmed objective response rate (cORR) was maintained at 41.3%, with an additional complete response noted. The safety profile remained manageable. These results support the potential of zanidatamab to improve outcomes for BTC patients.
Jazz Pharmaceuticals will present thirteen abstracts, including five late-breaking ones, at SLEEP 2024 held from June 1-5 in Houston. The presentations highlight new data from their sleep medicine portfolio, particularly focusing on narcolepsy and idiopathic hypersomnia. Key presentations include the Phase 4 XYLO study addressing systolic blood pressure changes when switching to low-sodium Xywav®, and a post-hoc analysis of Xywav's efficacy and safety. Additional studies explore the clinical burden, healthcare costs, and treatment outcomes of those with idiopathic hypersomnia. The abstracts indicate Jazz's ongoing commitment to advancing treatments for serious sleep disorders.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will participate in two key investor conferences in June 2024: the Jefferies Global Healthcare Conference on June 6 and the Goldman Sachs 45th Annual Global Healthcare Conference on June 12. The company will conduct fireside chats at both events, with audio webcasts available on their website. Jazz Pharmaceuticals focuses on developing medicines for serious diseases, including sleep disorders, epilepsy, and cancer. With headquarters in Dublin, Ireland, Jazz operates globally, driven by a patient-focused and science-driven approach.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that the FDA has granted Priority Review for zanidatamab, a HER2-targeted bispecific antibody, to treat HER2-positive metastatic biliary tract cancer (BTC). The target action date is set for November 29, 2024. If approved, zanidatamab will be the first HER2-targeted treatment for this condition. The submission is based on results from the Phase 2b HERIZON-BTC-01 trial, which showed a 41.3% confirmed objective response rate. Further data from this trial will be presented at the ASCO Annual Meeting 2024. Additionally, the Phase 3 HERIZON-BTC-302 trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy.
Jazz Pharmaceuticals announced a collaboration with Life Science Cares to enhance social impact via employee volunteerism in the U.S. This partnership aligns with Jazz's commitment to local communities where its employees reside. Life Science Cares leverages life sciences' financial and human capital to address poverty and inequality. The program will operate around Jazz's U.S. offices in Palo Alto, Philadelphia, and San Diego, encouraging employees to engage in meaningful volunteer activities. Jazz's Global Volunteer Day Policy allows employees to dedicate one paid workday annually to volunteer. Life Science Cares, active since 2016, has invested over $16 million and 55,000 volunteer hours to combat socio-economic disparities.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in the BofA Securities 2024 Global Health Care Conference on May 15, 2024, in Las Vegas. The fireside chat will be held at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST. An audio webcast will be available via the Investors section of the Jazz Pharmaceuticals website.
Jazz Pharmaceuticals plc is a global biopharma company focused on developing life-changing medicines for serious diseases. The company has a diverse portfolio of treatments for sleep disorders, epilepsy, and cancer. Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with a commitment to serving patients worldwide.
Jazz Pharmaceuticals reported a 12% year-over-year revenue increase driven by key growth drivers Xywav, Epidiolex, and Rylaze. They submitted zanidatamab BLA for 2L BTC, expect to launch in 2025, and affirmed 2024 total revenue guidance at $4.0 to $4.2 billion. Various pipeline catalysts and near-term data releases are anticipated. Financials showed a decrease in Xyrem net product sales, an increase in Epidiolex/Epidyolex net product sales, and Rylaze/Enrylaze net product sales. The company provided extensive updates on their key commercial products, pipeline highlights, financial highlights, and 2024 financial guidance.
Jazz Pharmaceuticals is focusing on taking actions to positively impact the planet during Earth Month. They are reflecting on steps to become more conscious of their actions and promoting sustainable practices. For more information, read their Corporate Sustainability and Social Impact Report.
Summary not available.